Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus

References

• Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842–7.
   PubMed Web of Science ®Google Scholar
• Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889–96.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Takada Y, Haga H, Nabeshima M, Marusawa H, Ito T, Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008;85:855–62.
   PubMedGoogle Scholar
• Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004;78:1308–11.
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Makuuchi M. Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol 2006;12:4461–5.
   PubMedGoogle Scholar
• Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008;14:1766–77.
   PubMed Web of Science ®Google Scholar
• Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008;28:450–7.
   PubMed Web of Science ®Google Scholar
• Dinges S, Morard I, Heim M, Dufour JF, Mullhaupt B, Giostra E, Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009;11:33–9.
   PubMedGoogle Scholar
• Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032–8.
   PubMedGoogle Scholar
• Sugawara Y, Makuuchi M. Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience. Clin Gastroenterol Hepatol 2005;3(10 Suppl 2):S122–4.
   PubMedGoogle Scholar
• Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086–97.
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007;46:1688–94.
   PubMed Web of Science ®Google Scholar
• Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int 2009;23:580–8.
   PubMedGoogle Scholar
• Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010 (In press).
   Google Scholar
• Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77–81.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006;78:83–90.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007;46:403–10.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005;48:372–80.
   PubMed Web of Science ®Google Scholar
• Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067–76.
   PubMed Web of Science ®Google Scholar
• Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53–8.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007;79:1686–95.
   PubMed Web of Science ®Google Scholar
• Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990;87:9524–8.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425–33.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97–103.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004;189:964–70.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009;81:452–8.
   PubMedGoogle Scholar
• Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol 2010;52:672–80.
   PubMedGoogle Scholar
• Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632–8.
   PubMed Web of Science ®Google Scholar
• Ogata K, Ide T, Kumashiro R, Kumada H, Yotsuyanagi H, Okita K, Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Hepatol Res 2006;34:35–40.
   PubMedGoogle Scholar
• Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokaddem F, Wain E, Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004;20:15–22.
   PubMedGoogle Scholar
• Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452–7.
   PubMed Web of Science ®Google Scholar